Marshall Wace, LLP Gain Therapeutics, Inc. Transaction History
Marshall Wace, LLP
- $74.4 Billion
- Q1 2025
A detailed history of Marshall Wace, LLP transactions in Gain Therapeutics, Inc. stock. As of the latest transaction made, Marshall Wace, LLP holds 196,026 shares of GANX stock, worth $395,972. This represents 0.0% of its overall portfolio holdings.
Number of Shares
196,026
Previous 91,738
113.68%
Holding current value
$395,972
Previous $187,000
100.0%
% of portfolio
0.0%
Previous 0.0%
Shares
2 transactions
Others Institutions Holding GANX
# of Institutions
37Shares Held
3.1MCall Options Held
8.4KPut Options Held
8.7K-
David Einhorn Greenlight Capital Inc | New York, Ny588KShares$1.19 Million0.1% of portfolio
-
Dme Capital Management, LP New York, NY566KShares$1.14 Million0.05% of portfolio
-
Geode Capital Management, LLC Boston, MA282KShares$570,0660.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA255KShares$515,0790.0% of portfolio
-
Joel Greenblatt Gotham Asset Management, LLC | New York, Ny154KShares$311,0470.0% of portfolio
About Gain Therapeutics, Inc.
- Ticker GANX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 11,883,400
- Market Cap $24M
- Description
- Gain Therapeutics, Inc., a biotechnology company, engages in developing various therapies to treat diseases caused by protein misfolding. It focuses on rare genetic diseases and neurological disorders. The company uses its Site-Directed Enzyme Enhancement Therapy platform to discover allosteric sites on misfolded proteins and identify proprietar...